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Humans, birds, and some primates do not express the uric
acid degrading enzyme urate oxidase (UOX) and, as a result, have
plasma uric acid concentrations higher than UOX expressing
animals. Although high uric acid concentrations are suggested
to increase the antioxidant defense system and provide a health
advantage to animals without UOX, knockout mice lacking
UOX develop pathological complications including gout and
kidney failure. As an alternative to the knockout model, RNA
interference was used to decrease UOX expression using stable
transfection in a mouse hepatic cell line (ATCC, FL83B). Urate
oxidase mRNA was reduced 66% (p < 0.05) compared to wild
type, as measured by real time RT-PCR. To determine if UOX
knockdown resulted in enhanced protection against oxidative
stress, cells were challenged with hexavalent chromium (Cr(VI))
or 3-morpholinosydnonimine hydrochloride (SIN-1). Compared
to wild type, cells with UOX knockdown exhibited a 37.2 ± 3.5%
reduction (p < 0.05) in the electron spin resonance (ESR) signal
after being exposed to Cr(VI) and displayed less DNA fragmentation (p < 0.05) following SIN-1 treatment. Cell viability
decreased in wild type cells (p < 0.05), but not cells with UOX
knockdown, after treatment with SIN-1. These results are consistent with an increased intracellular uric acid concentration and
an increased defense against oxidative stress.

Introduction
In the genomes of both prokaryotes and eukaryotes lies the
gene for the uric acid degrading enzyme, urate oxidase (UOX,
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EC 1.7.3.3.), however, not all organisms express this gene. Among
those organisms in which its expression is silenced are humans,
birds, some primates, terrestrial reptiles and most insects. In these
organisms, uric acid is excreted as the terminal product of purine
degradation. In UOX expressing animals, UOX further degrades
uric acid to allantoin, the terminal product of purine degradation.
When UOX is expressed, the plasma concentration of uric acid is
much lower than in those animals that do not express the enzyme.
For example, in humans the normal range of serum uric acid is
200 to 400 μM, which is similar to that found in birds1 and 10 to
20 times that found in UOX expressing animals. Without UOX,
humans have achieved a state of hyperuricemia that approaches
the saturation point2,3 and, as a result, gout is a prevalent disease
in humans.
The association of hyperuricemia with hypertension4 and
cardiovascular disease (CVD)5 in humans, as well as the pathological complications resulting from uric acid crystallization in the
kidneys and joints makes the functional advantage of a lack of UOX
expression unclear. One widely accepted theory is that increased
serum uric acid may provide humans with an increased antioxidant
capacity for free radical scavenging, which may reduce the accumulation of oxidative damage and extend the life span.6 Supporting
this theory is the positive correlation between plasma urate and
life span among the primate species.7 Also, numerous reports
cite the ability of uric acid to protect cellular components from
reactive oxygen and nitrogen species,8,9 which may contribute to
animal longevity. However, uric acid exhibits pro-oxidant10,11 and
pro-inflammatory12 properties when concentrations are elevated,
suggesting that hyperuricemia may be involved in the onset and/
or exacerbation of diseases associated with high levels of oxidative
stress, like CVD,13,14 hypertension15,16 and ischemic stroke.17
To further understand the potential role that uric acid has in
longevity, disease development and disease treatment, a mouse
model for hyperuricemia was created that lacks urate oxidase
expression.18,19 These mice were severely hyperuricemic, exhibiting serum uric acid concentrations ten times higher than that
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found in the wild type mice and twice that found in humans. Uric
acid crystals developed in the kidneys and led to urate nephropathy
and nephrogenic diabetes insipidus, resulting in dehydration and
death of most mice within several weeks of birth. The extreme
hyperuricemia and resultant pathological complications obviate
the use of these mice, therefore a more appropriate animal model
of human hyperuricemia should be established. Using RNA interference to reduce UOX expression in mice may elevate serum uric
acid without it reaching the lethal concentrations observed in the
knockout model, thereby potentially providing an effective experimental model of human hyperuricemia.
The objective of this study was to utilize RNA interference to
“knockdown” UOX expression in a mouse hepatic cell line and
to determine the effects on the oxidative stress response. This will
provide a direct link between reduced UOX expression
and the resultant increased protection this affords from
oxidative damage by reactive species. The advantage of
using small interfering RNAs is that this approach affords
an element of control over UOX gene expression and
subsequently the degree to which serum uric acid concentrations are elevated.

Figure 1. Urate oxidase mRNA abundance in wild type cells, negative
control cells, or cells with urate oxidase (UOX) knockdown. Urate oxidase
mRNA abundance is scaled to wild type levels, which is set at 100%. Bars
represent means ± SEM, n = 2. Different letters indicate differences (p <
0.05) between cell lines.

Results
There was a 66% knockdown in UOX mRNA (Fig. 1)
(p < 0.05) in the cell line expressing shRNA sequence 1.
This was the numerically greatest level of UOX knockdown among the cell lines expressing shRNA sequences Figure 2. Electron spin resonance in wild type and cells with urate oxidase (UOX)
that target UOX. The reduction of UOX mRNA in the silencing. Spectra (A and B) were generated in the presence of wild type cells and
cell lines expressing shRNA sequences 2–4 ranged between spectra (C and D) were generated in the presence of cells with urate oxidase knock0% and 60% of wild type levels (data not shown). No down. Only cells in spectra (A and C) were exposed to Cr(VI) at 200 μM.
difference in UOX mRNA abundance between the wild type cell
line and the cell line serving as the negative control was detected
(p > 0.05).
Representative ESR spectra are shown in Figure 2. This spectrum
consists of a 1:2:2:1 quartet with hydrogen and nitrogen splitting
constants of aH = aN = 14.9 G. Based on these splitting constants,
the quartet was assigned to a DMPO/-OH adduct, which can also
be generated by decomposed superoxide free radicals. There was no
measurable signal in cells not exposed to Cr(VI). When exposed
to Cr(VI), cells with UOX knockdown exhibit a 37% smaller
(p < 0.05) free radical signal than wild type cells.
Data presented in Figure 3 were tested for fit to a linear regres- Figure 3. Cell viability of wild type (diamonds), negative control (squares)
sion line to determine if SIN-1 exposure had an effect on cell and urate oxidase (UOX) knockdown (triangles) cell lines exposed to variviability. In both the wild type and negative control cell lines, cell ous concentrations of 3-morpholinosydnonimine hydrochloride (SIN-1) for
24 hours. Data points represent means ± SEM, n = 2. Data within each
viability decreased with increasing concentrations of SIN-1 (p < cell line were scaled to the viability of cells exposed to 0 μM SIN-1, which
0.01). However, no significant decrease in cell viability occurred was set at 100% viability. The regression line for each cell type is indiin the cell line with UOX knockdown (p = 0.99). Across all cells cated. Wild type: p < 0.0001, R2 = 0.78; Negative Control: p < 0.0001,
2
2
lines, after 24 hours of exposure to 1,000 μM SIN-1, there was no R = 0.51; UOX Knockdown: p > 0.9, R < 0.1.
cell survival (data not shown).
Tail length, which was measured in arbitrary units and indicative tail length increased with an increase in SIN-1 concentration (p <
of the extent of DNA fragmentation, from all cell line by treat- 0.05). Across SIN-1 concentrations, the overall tail length of wild
ment combinations was quantified and is presented in Figure 4. type cells and the negative control cell line was 27.5 ± 0.9 and 27.0
Analysis of variance indicated a main effect of cell line and SIN-1 ± 0.9, respectively, which were longer (p < 0.05) than the 22.0
concentration, as well as a cell line by SIN-1 concentration interac- ± 0.9 overall tail length in the cells with UOX silencing. There
tion, on tail length (p < 0.05). Pooled across all cell lines, comet was no difference in tail length between cell lines not exposed to
94
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Figure 4. Comet tail length (arbitrary units) of the wild type (black bars),
negative control (gray bars) and urate oxidase (UOX) knockdown (white
bars) cell lines exposed to various concentrations of 3-morpholinosydnonimine hydrochloride (SIN-1). Bars represent means ± SEM. Letters
represent significant differences (p < 0.05) between cell lines within the
same concentration of SIN-1.

SIN-1. The UOX knockdown cells had a significantly shorter tail
length (p < 0.05) than both wild type and negative control cells at
250 μM and 1,000 μM SIN-1. When exposed to 500 μM SIN-1,
cells with UOX knockdown had shorter tails (p < 0.05) than only
the negative control cell line.

Discussion
In the present experiment, short interfering RNAs were used to
silence UOX mRNA approximately 66% compared to wild type.
Exposure to Cr(VI) resulted in a less intense ESR signal in cells
with UOX silencing, indicative of lower hydroxyl and/or superoxide radical concentrations. In wild type and negative control
cells, cell viability decreased with increasing concentrations of
the peroxynitrite producing chemical, SIN-1, up to the 500 μM
level. This relationship was not observed in cells with urate oxidase
silencing. The comet assay, used to detect DNA fragmentation
induced by SIN-1, indicated that cells with UOX silencing had less
DNA denaturation when exposed to SIN-1. These aforementioned
findings are consistent with increased protection from oxidative
damage in UOX silenced cells.
The effect of reducing UOX mRNA on intracellular uric
acid concentrations is unknown. Attempts were made to assess
concentration differences but technical difficulties prevented
accurate quantification. However, because of existing differences
in the physiological responses to oxidative stimuli between the cell
lines, it is likely that an increase in the intracellular concentration
of uric acid occurred with UOX mRNA silencing. Additionally,
neither the transfection conditions nor the expression of the
shRNA affected the handling of oxidative stress, since the effects
of oxidative stress in the negative control cell line remain similar
to wild type cells. Reducing UOX activity levels with oxonic acid,
a competitive inhibitor of the enzyme, is effective in increasing
circulating uric acid concentrations.20 Therefore, assuming the
intracellular concentration of uric acid is increased in cells with
UOX silencing, these results support the role of uric acid as an
antioxidant.
Hexavalent chromium is a carcinogen in both human and
animal models.21 The most documented evidence of Cr(VI)
www.landesbioscience.com

toxicity is from inhalation of the molecule, which is most apparent
in the increased rate of lung,22 kidney, prostrate and bladder
cancers23 and mental illness22 in those exposed in the workplace.
Once in the cell, Cr(VI) is reduced by intracellular antioxidants
like glutathione, ascorbic acid and cysteine or through the intermediates Cr(V) and Cr(IV) to trivalent chromium (Cr(III)).24
Trivalent chromium can interact with DNA to form Cr-DNA
adducts,25 which can induce apoptosis or mutagenesis. Interaction
of the hexavalent chromium with cellular components can induce
production of hydroxyl and superoxide free radicals detected by
ESR, inducing oxidative stress and causing oxidative damage.26,27
The present study indicates that cells with UOX silencing are
exposed to less reactive oxygen species than wild type cells when
treated with Cr(VI). This supports an existing theory that, in
vitro, uric acid was effective at reducing DNA damage induced
by Cr(III) exposure.28 The probable increase in the intracellular
concentration of uric acid either contributes to greater free radical
scavenging or reduces the rate of free radical production, or a
combination of both, thus protecting cellular components from
Cr(VI)-induced reactive oxygen species damage. This raises the
possibility that uric acid may be a therapeutic agent for Cr(VI)
exposure, a concept that warrants further investigation.
In addition to Cr(VI), SIN-1 was used in the present experiment to induce oxidative stress. Decomposition of SIN-1 in
solution at pH > 5 causes production of superoxide and nitric
oxide. Together, these chemicals spontaneously form peroxynitrite,
which is detected both in the media29 and inside cells.30 It has
been well established in numerous cell types that treating cells
with SIN-1 causes intracellular oxidative stress and accumulation
of intracellular markers of oxidative damage in a dose-dependent
manner, resulting in a reduction in cell viability.
Exposure of human lymphoid blastoma cells to SIN-1 concentrations between 1 mM and 5 mM caused a dose-dependent increase
in cell death.31 This is supported by data in human premonocytic
cells where a reduction in viability was found after treatment of cells
with 1 mM and 2 mM SIN-1.32 Interestingly, rodent cell culture
exhibits a lower tolerance to SIN-1-induced reduction in viability.
In the present experiment, wild type cell viability began to decrease
when the SIN-1 concentration in the media was 100 μM and
decreased to approximately 50% viability when the concentration
reached 500 μM, while a 1 mM concentration resulted in no viable
cells after 24 hours. The 50% reduction in cell viability at 500 μM
was also observed in rat adrenal gland cell culture.33 Biological fluids
have a quenching effect on reactive species produced by SIN-1,34 so
the origin of animal sera used to supplement growth media likely
influences SIN-1-induced peroxynitrite exposure.
Incubating cells with antioxidants or antioxidant enzymes
reduces the toxicity of SIN-1 in cell culture. Exposure to 1 mM or
5 mM uric acid31,33 or a combination of catalase and superoxide
dismutase31 limited the reduction in cell viability or cell death
caused by SIN-1. In the present experiment, the maintenance of
cell viability between 100 μM and 500 μM SIN-1 that occured
with UOX silencing supports the concept that intracellular uric
acid is increased in these cells, protecting the cellular components
from oxidative damage that leads to cell death.
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One of the specific sites of SIN-1 induced oxidative damage
is denaturation of genomic DNA. The data presented here agrees
with numerous reports utilizing the comet assay as an indicator of
DNA damage induced by SIN-1 in human lymph cells29,31 and
Chinese hamster fibroblasts35 that was preventable by inclusion of
catalase,29 lycopene or β-carotene35 in the cell culture media. The
ability of antioxidants or antioxidant enzymes to limit the strand
breaks implies that an increased antioxidant capacity is present in
cells with UOX silencing and presumably this is an increased uric
acid concentration.
As demonstrated in this study, RNA interference can be used
in a mouse-derived cell culture system to reduce UOX expression,
which resulted in increased protection against oxidative stress.
Additionally, the results in the present study suggest that intracellular uric acid concentration was not increased to a level that
became pro-oxidative. The next logical experiment would be to
apply this concept in a living mouse. The advantage of retaining
a certain level of UOX expression, as opposed to eliminating it
completely as in the knockout models, is that the elevation of
uric acid to lethal levels can be avoided. Therefore, moderate to
dramatic increases in circulating uric acid concentrations would
likely occur proportional to the degree of UOX knockdown which
would allow for further investigation into the role that uric acid
may play in disease treatment and prevention.
Several reports have established an association between serum
uric acid and death due to cardiac mortality36-38 and some
evidence indicates that hyperuricemia can predict development of
hypertension,39,40 obesity,41 kidney disease42 and diabetes.43,44 It
has been suggested that treating hyperuricemia with allopurinol
in combination with anti-hypertensive drugs and lipid-lowering
therapies may synergistically act to reduce the risk of cardiovascular disease.45 Additionally, using allopurinol to reduce uric acid
exerts beneficial effects on inflammatory indices in patients with
ischemic stroke.46,47 Therefore, mice exhibiting hyperuricemia via
UOX knockdown would help to better understand the associations
between uric acid and diseases that are characterized by excessive
oxidative stress.

Materials and Methods
Plasmid construction. Plasmid pSilencer4.1-CMVneo (Ambion,
Austin, TX), was selected for stable expression of short hairpin
RNA (shRNA) sequences in mammalian cells while conferring
resistance to antibiotics. Sequences used for RNA interference
were generated against mouse UOX and the following four sense
sequences were chosen (1) 5'-AGC CUU CCG AAC AUU CAC
U-3', (2) 5'-ACC UCA AGG UCU UGA AAA C-3', (3) 5'-GGA
CUG AUC AAC AAG GAA G-3' and (4) 5'-ACC UAC ACG
GUG AUA AUU C-3'. The loop sequence, TTCAAGAGA, joined
the sense and antisense sequences in the hairpin structure. An additional “scrambled” shRNA sequence that was designed by Ambion
to have limited similarity to the mouse genome database served as
a negative control and was ligated into pSilencer4.1-CMVneo.
Cell culture and transfection conditions. A mouse hepatic cell
line was purchased from ATCC (designation: FL83B, Manasass,
VA) and grown per supplier’s instructions in F-12K media (ATCC,
96

Manasass, VA) supplemented with 10% fetal bovine serum and
500 I.U. penicillin/mL, and 500 μg streptomycin/mL. On the day
of transfection, 6 x 104 cells were plated per well with antibioticfree growth media in a 24-well plate with 48.5 μL Opti-MEM
media (Invitrogen), 1.5 μL XP-sport (Ambion) and 0.5 μg
pSilencer4.1-CMVneo with the shRNA to either UOX or the
nonsense sequence per transfection reagent protocol. The transfection was completed for each of the four shRNA sequences for UOX
knockdown and the nonsense shRNA sequence. Six hours posttransfection, the media was replaced with antibiotic containing
growth media. Twenty-four hours post-transfection, cells were
expanded to a 60-mm cell culture dish with growth media supplemented with 900 μg G418/mL media. Cells were exposed to G418
and surviving colonies were selected and expanded.
Real time RT-PCR. Real time RT-PCR was used to analyze
mRNA knockdown in cell lines using acidic ribosomal protein
(ARP) as a reference gene. A T-75 flask of cells was washed with
5 mL of cold Hanks balanced salt solution and layered with
3 mL Trizol LS (Invitrogen) and RNA was isolated according to
manufacturer’s protocol. RNA was quantified and the quality was
determined using A260:A280. Two μg of RNA was reverse transcribed using oligo-dT primers (Promega) and MMLV (Promega)
per manufacturer’s protocol. Complementary DNA was diluted
1:4 with nuclease free water and 10 μL (for UOX PCR) or 5 μL
(for ARP PCR) was used in a 50 μL PCR reaction with 25 μL
2X SYBR Green Supermix (BioRad, Hercules, CA), 1.25 μM
forward ARP primer (5'-CAA CCC AGC TCT GGA GAA AC-3')
and 1.25 μM reverse ARP primer (5'-GTG AGG TCC TCC
TTG GTG AA-3') or 1.25 μM forward UOX primer (5'-TGG
AGA CTT CAA CGG CTT CT-3') and 1.25 μM reverse UOX
primer (5'-TGG CCC ATA GAT CTC CTT TG-3'). The real
time RT-PCR protocol was performed on a BioRad iCycler IQ
Detection System (Hercules, CA). The protocol began with a
“hot-start” at 95°C for 5 minutes, followed by a cycle of 95°C for
15 seconds, 60°C for 30 seconds and 72°C for 30 seconds. The
cycle was completed forty times, followed by melt curve analysis.
Real-time RT-PCR data was analyzed using the efficiency corrected
relative expression method.48 The cell line demonstrating the
greatest UOX knockdown, the negative control cell line, and the
wild type cell line were used in subsequent experiments to investigate the oxidative stress response.
Electron spin resonance. Electron spin resonance (ESR) spin
trapping was used to detect short-lived reactive oxygen intermediates using an established method.49 All ESR measurements were
conducted using a Bruker EMX spectrometer (Bruker Instruments
Inc., Billerica, MA) with a flat cell assembly and an Acquisit
program was used for data acquisition and analysis. The ESR spectrometer settings were: receiver gain, 5.02 x 104; time constant,
40.96 ms; modulation amplitude, 0.50 G; scan time, 41.94 s;
magnetic field 3480 ± 100 G. Experiments were performed at
room temperature, under ambient air. Signal intensity was quantified by measuring average distance (mm) using the peak to peak
method. Each sample (500 μL) contained 5 x 105 cells in phosphate buffered saline, 200 mM 5,5-dimethyl-1-pyrroline-N-oxide
(DMPO), and 0.0 or 200 μM hexavalent chromium (Cr(VI)) to
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induce radical formation. Samples (n = 5) were incubated for 37°C
for five minutes before loading into the flat cell assembly for free
radical detection.
Cell viability. Cell viability was used to determine the ability
of the cells to survive a reactive nitrogen species challenge. On
day one, 1 x 104 cells were plated in a well of a 96-well plate and
grown overnight. On day two, duplicate wells, the media was
replaced with 100 μL media containing various concentrations
of 3-morpholinosydnonimine hydrochloride (SIN-1). After 24
hours of SIN-1 exposure the cell viability was determined using
the MTT assay (Cayman Chemical, Ann Arbor, MI) per manufacturer’s protocol.
DNA fragmentation. Cells were seeded, 1.5 x 105 per well, in
a 12-well plate and allowed to grow overnight. On day two, media
was replaced with media that contained various concentrations of
SIN-1. After three hours, cells were harvested and resuspended in
500 μL of ice-cold PBS. Fragmented DNA was detected using the
Comet Assay per manufacturer’s protocol (Trevigen, Gaithersburg,
MD). The extent of DNA fragmentation was determined by
measuring tail length beginning at center of the cells to the left
rim of SYBR green fluorescence using Optimas 6.5 Image analysis
software (Media Cybernetics, Silver Spring, MD).
Statistics. Data were analyzed by linear regression analysis or
analysis of variance with PC-SAS general linear models procedure
for significant differences among treatment means. In the event
of a significant F value, the LSD procedure was used for means
comparisons. Differences were considered significant at p < 0.05.
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